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means of the two devices were almost similar in each 
direction except the vertical, lateral, and pitch directions (t-
test, p < 0.0001), whereas the maximal deviations in the 
three directions were slight. The SDs were not statistically 
different in each direction except the lengthwise and roll 
directions (F-test, p < 0.05), although the SDs were small in 
the corresponding two directions for CID. 
 
Conclusion: This study suggested that 3DID could show 
positional accuracy almost similar to that of CID. However, 
further investigation is needed for use in clinical practice. 
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Purpose or Objective: CTCAE version 3 is an observation 
based grading system for oral mucositis whereas version 4 is 
based on function and intervention. Although version 4 has 
been widely adopted in clinical trials there is limited data on 
its correlation with version 3 from which considerable 
radiobiological data has been derived. The purpose of this 
study was to assess the frequency of discrepancy between 
these two grading systems. 
 
Material and Methods: Oral mucosal reactions of patients 
undergoing chemoradiation or radiation alone for oral or 
oropharyngeal cancer were graded by three radiation 
oncologists in weekly on treatment and post treatment 
clinics. CTCAE version 3 and 4 mucositis grading and patient 
factors were recorded prospectively. Differences in the rate 
of discrepancy were compared by time since the 
commencement of radiotherapy, synchronous agent and 
patient age. 
 
Results: 485 measurements were recorded for 64 patients. 
Grading from version 3 and version 4 were equal in 270 (56 %) 
measurements. In the 215 (44%) measurements where version 
3 and version 4 were not equal, discrepancies were seen in: 
Week 0-4 = 79/179 (44%); Week 5-8 = 60/163 (37%); > week 8 
= 76/143 (53%) (p=0.02); patients receiving platinum agents = 
113/316 (36%) or cetuximab= 48/70 (69%) (p<0.01); patients 
> 70 years = 26/57 (46%) or < 50 years = 21/68 (31%) (p=0.09). 
 
Conclusion: Statistically significant discrepancies were seen 
when patients receiving platinum agents were compared with 
those receiving cetuximab and in those measurements 
performed following treatment completion. These initial 
results suggest that functional/interventional based grading 
systems should be used with care in dose escalation studies 
where the healing of acute mucositis may be related to 
subsequent late damage. 
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Purpose or Objective: Acute esophagitis (AE) is a common 
side-effect of radiotherapy (RT) for lung cancer. Previous 
predictive modelling studies focussed on clinical criteria 
(such as CTC) for significant AE (such as G2 or higher). Our 
clinic uses an integrative patient care approach where Nurse-
RTTs routinely monitor symptoms and provide nursing 
interventions to manage side-effects. Therefore, Nurse-RTTs 
include with clinical scoring a note of actual symptoms 
mentioned by the patient during consultations, such as 
swallowing pain (SP). A retrospective audit of 131 patients 
was used to examine correlative patterns for SP, and hence 
to develop predictive models for SP before the start of RT. 
We propose that a predictive model will facilitate nurse/RTT-
led efforts to reduce the impact of SP on patient comfort, 
overall QoL and clinical workflow. 
 
Material and Methods: An electronic journal audit was 
performed for patients commencing curative RT for lung 
cancer between January 2013 and March 2015. All NSCLC and 
SCLC patients were included, as well as various 
dose/fractionation, chemotherapy and medication schedules. 
Exported treatment plan DVHs were merged with nursing 
data. The highest score following weekly assessments of AE 
during radiotherapy was recorded, as was the appearance of 
SP and the time point at which it was mentioned. Predictive 
models of SP were developed using multivariable regression 
and machine learning algorithms. 
 
Results: The most typical patient was treated for NSCLC at 
60-66Gy normo-fractionated with concurrent chemotherapy. 
Acute esophagitis (CTC grade 1 or higher) was observed in 
110/131 (84%) and patient-reported SP in 99/131 (76%). Pain 
medication prior to RT was marginally protective against SP 
but was not statistically significant in single-parameter 
analysis (OR 0.58, 95%CI 0.24–1.41, p=0.21). A strongly 
significant dose-volume response exists between SP and 
radiobiologically-adjusted dose to the hottest 1cc of the 
esophagus. Predictive models of SP with repeated cross-
validation accuracy of 78-84% were developed (sensitivity 88-
89%, specificity 48-75%). Trained machine learning models 
correctly predicted SP 76-84% of the time in an unseen 
validation cohort of 25 patients (sensitivity 94-100%, 
specificity 25-62%).  
 
Conclusion: An integrative nursing care approach in the RT 
clinical workflow has been used to monitor symptoms and 
intervene for treatment-related pain. The risk of one 
particular patient-centred symptom, SP, can be sensitively 
predicted with nursing and treatment planning variables. A 
future nurse-led interventional study is planned, using 
predictive modelling for swallow pain, to examine the 
possible effects of pre-treatment pain-medication or 
corticosteroids on reducing dependence on additional pain 
medication.  
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Purpose or Objective: The aim of this study was to 
investigate systemic set-up errors in head and neck (H&N) 
cancer treated with intensity modulated radiation therapy 
(IMRT) by kilovoltage (kV) cone-beam computed tomography 
(CBCT) evaluation. 
 
Material and Methods: Between September 2014 and August 
2015, 360 CBCT in 60 patients (pts) affected by histological 
confirmed H&N cancer treated with IMRT technique were 
analyzed. The majority of patients treated 45 (75 %) were 
male and only 15 (25%) were female; median age was 68 
years (range 44-88 years). The type of head and neck cancer 
treated were, oropharynx , hypopharynx, nasopharynx, larynx 
, tonsil, oral cavity and parotid cancer. All patients 
underwent planning Computerized Tomography (CT) 
simulation on supine position on a GE LightSpeed RT 16 CT 
Simulator for 2.5 mm slice thicknesses. As immobilization 
system we utilized a head-shoulder thermoplastic mask (Easy 
Frame (Candor TM)). The CT data sets were transferred to 
the Focal and Varian Eclipse treatment planning system 
through DICOM network. The target delineation was 
contoured by one Radiation Oncologist and according to 
(ICRU62) the PTVs volumes were generated by adding a 3-mm 
margin in all directions to the respective CTVs. The 
prescribed dose was 66 Gy in 30 fractions delivered to GTVs, 
54-63 Gy in 30 fractions to CTVs. The IMRT plans were 
created on the Varian Eclipse treatment planning system 
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using coplanar beams with 6 MV photons and the treatment 
was performed with DHX LINAC, VARIAN System. 
Pretreatment kV CBCT images were obtained at 1, 2 and 3 
day of irradiations set-up corrections were made before 
treatment if the translational setup error was greater than 3 
mm in any direction. Subsequently a weekly kV CBCT was 
repeated for whole duration of treatment. 
 
Results: A total of 360 CBCT scans were acquired and 
analyzed. The systemic errors results 1.26 mm (SD ± 0.177) in 
RL direction, 1.25 mm (SD ± 0.187) in SI direction and 1.8 mm 
(SD ± 0.255 in AP direction. The range of deviations were 0-9 
in RL directions, 0-5 mm in SI direction and 0-10 mm in AP 
direction. The frequencies of setup errors > 3 mm in RL 
direction was 3.9 %, in SI 8 % and AP directions 15.5 %, 
respectively. Analyzing the CBCT before set-up corrections 
the frequencies of set-up error > 3 mm were 17.8 %, 10.6 % 
and 5.6 % in AP, SI and RL respectively. After set-up errors 
corrections (corrections via couch shifts or patient 
repositioning) these rates were reduced to 13,3%, 7.2 and 2.2 
% in PA, SI and RL direction, respectively. 
 
Conclusion: The results of our study confirmed that image 
guidance with kV CBCT represents an effective tool for 
measuring set-up accuracy in the treatment of H&N cancer 
patients. This study suggested that kV CBCT once a week is 
adequate to overcome the problem of set-up errors in head 
and neck cancer treated with IMRT technique. 
 
Poster Viewing: 6: Clinical: Lung, palliation, sarcoma, 
haematology  
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Purpose or Objective: In 1998, our institute developed a 
class-solution for intensity-modulated radiotherapy (IMRT) for 
lung cancer. Clinical implementation of IMRT gradually 
started as of 2002. This retrospective study reports on 
toxicity and overall survival (OS) of non-small cell lung cancer 
(NSCLC) patients treated with curative intent using the 
described IMRT set-up. 
 
Material and Methods: Between 2002 and 2013, a total of 
434 patients with a thoracic malignancy have been treated 
with IMRT in the Radiation Oncology department of the Ghent 
University Hospital. Those with NSCLC and receiving a total 
dose of ≥60Gy with fraction size <3Gy, a total 223, were 
retrospectively reviewed and formed the basis of this 
analysis. Clinical endpoints of OS and acute and late 
pulmonary and esophageal toxicity grade ≥3 were analyzed in 
relation to chemotherapy (concomitant vs. sequential 
chemoradiotherapy (CRT) vs. no chemotherapy) and use of 
standardized dose-volume evaluation criteria. Analysis was 
performed in SPSS using Kaplan-Meier curves for survival and 
Chi-square analysis for toxicity.  
 
Results: Median follow-up time is 18 months (range 2-125). 
The table reports patient, tumor and treatment 
characteristics. OS was scored for all patients as date of 
death (N=140) or, if missing, as date of last consultation in 
our hospital (N=83). Acute and late toxicity data were 
available for 219 and 95 patients respectively. Median OS for 
the entire population was 25 months, 5 year OS 24%. OS was 
significantly better for patients treated with concomitant 
CRT than for those undergoing the sequential approach 
(median OS 30 months vs. 23; 5 years OS 32% vs. 12%) 
(p<0,05). Acute grade ≥3 pulmonary toxicity occurred in 7,8% 
of the patients, without significant difference between 
concurrent and sequential CRT. Acute grade ≥3 esophageal 
toxicity occurred in 5,5% of patients overall; and was 
significantly worse (p<0,01) in patients treated with 
concomitant CRT compared to sequential CRT: 10,4% vs. 4,3% 
respectively. Late grade ≥3 pulmonary and esophageal 
toxicity was observed in 3,3% and 0% respectively; late grade 
2 toxicity in 13,2% and 1,4% of the cases respectively. 
Although there was a trend towards reduced esophageal 
toxicity, the use of standardized dose-volume evaluation 
criteria (N=38) did not influence pulmonary (p=0.60) nor 
esophageal (p=0.08) toxicity significantly. 
 
Conclusion: In spite of the low 5-year OS in patients 
undergoing sequential CRT, the entire NSCLC population 
treated with IMRT in our institution obtained OS in line with 
that reported in the literature. IMRT further confirms the 
potential for reduced toxicity as observed in other single-
center experiences. Regardless of the lack of documented 
significant impact, we are convinced that the use of 
standardized dose-volume evaluation criteria has contributed 
to this positive outcome and is a precondition to exploit the 
full potential of IMRT in NSCLC.  
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Purpose or Objective: Respiratory movement and anatomical 
changes of the lesion during radiotherapy are the main 
causes of target missing and/or irradiation of healthy lung 
tissue. The organ motion control and the correct 
identification of target volume (TV) contribute to manage 
these issues; however, the open question is if the adaptation 
of TV during treatment leads to an increased incidence of 
recurrences in the area of target reduction. The aim of this 
study is to evaluate patients' pattern of failure distinguishing 
“marginal”, in field and out of field recurrences. 
 
Material and Methods: In this prospective study, since 2010, 
locally advanced NSCLC patients treated with 
radiochemotherapy (RCT) underwent a weekly chest-CT 
simulation during therapy. In case of tumor's shrinkage, a 
new TV was delineated and then a new treatment plan 
outlined ("replanning"). At the end of treatment, patients 
were sent to follow-up. The patterns of failure were 
classified as: in field (persistence or recurrence in TV post-
"replanning"), "marginal" (recurrence in the area of initial TV 
excluded from the post-"replanning" TV) and out of field 
(recurrence outside of initial TV). We also evaluated distant 
failure. 
 
